Answers are grounded in this paper and cite their sources.
Objective: To describe the distribution of non-vaccine serotypes (NVTs) causing pediatric IPD in China, we conducted a retrospective multi-center pooled analysis of non-PCV13 Streptococcus pneumoniae isolates from 2009 to 2024. Methods: We pooled individual-level data from 863 pediatric IPD cases across the Chinese mainland (2009–2024). After deduplication and laboratory re-verification, 103 unique non-PCV13 isolates from 15 cities were included for serotyping, genotyping, and antimicrobial susceptibility testing. Data from the late-PCV13 period (2020–2024) were compared with pre- (2009–2016) and early-PCV13 periods (2017–2019). Results: Among 863 IPD strains, 121 (14.0%) were non-PCV13; 103 unique isolates were analyzed. The proportion of non-PCV13 isolates increased from 7.5% (2009–2016) to 11.0% (2017–2019) and 17.8% (2020–2024) (p < 0.01) among characterised isolates. These isolates comprised 36 serotypes, dominated by 15A (13.6%), 15B (8.7%), 15C (7.8%), and 23A (7.8%). PCV20-extended serotypes accounted for only 19.4%. Twenty-two serotypes emerged post-PCV13 introduction. Sixty-six sequence types (STs) were identified, led by ST11972 (8.7%), ST8589 (7.8%), and ST9396 (4.9%). Erythromycin and clindamycin resistance rates were 94.2% and 90.3%, respectively. Conclusions: Among available pediatric IPD isolates in mainland China, the relative proportion of non-PCV13 serotypes increased over time, although this trend cannot currently be accurately quantified or confirmed as being related to changes in population-level IPD incidence or to vaccine-driven serotype replacement. The considerable serotype and genotype diversity poses substantial challenges for expanded vaccine formulations and future surveillance.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: